Want to see SE:QLIFE full AI Analyst Report?
QLIFE Stock Chart & Stats
kr3.01
-kr0.24(-7.59%)
At close: 4:00 PM EST
kr3.01
-kr0.24(-7.59%)
Day’s Range― - ―
52-Week Rangekr1.20 - kr5.70
Previous CloseN/A
Volume24.68K
Average Volume (3M)97.19K
Market Cap
kr57.75M
Enterprise Valuekr27.25M
Total Cash (Recent Filing)kr6.63M
Total Debt (Recent Filing)kr8.71M
Price to Earnings (P/E)―
Beta1.51
Next Earnings
Aug 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.27
Shares Outstanding28,874,178
10 Day Avg. Volume81,486
30 Day Avg. Volume97,188
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-4.74
Price to Sales (P/S)109.73
P/FCF Ratio-1.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-126.16
Revenue Forecast (FY)kr116.00M
Bulls Say, Bears Say
Bulls Say
Proprietary Decentralized Diagnostics PlatformQLife’s core business centers on a proprietary platform for molecular diagnostics and near-patient testing. That structural focus aligns with long-term trends toward decentralized care and faster diagnostics, supporting durable addressable-market relevance and potential adoption by clinics and point-of-care users over months to years.
Consumables And Software Mix Supports Recurring RevenueThe company’s model combines instruments with consumable assays and software, a setup that can generate recurring revenue and customer lock-in once adoption scales. Consumables-driven revenue, if commercial traction improves, tends to be steadier and supports margin sustainability versus one-time instrument sales.
Recent Positive Shift In Reported EquityTTM equity turning positive signals some balance-sheet repair versus multi-year accumulated losses. A restored equity position can modestly improve lender and investor perceptions, easing access to financing and providing a small cushion for executing commercialization plans over the medium term.
Bears Say
Very Low And Declining RevenueTTM revenue of only 239k and a 27% decline indicate weak commercial traction and failure to scale. Persistently tiny sales make it difficult to leverage fixed costs, validate unit economics, or fund go-to-market investment internally, raising the risk that the business cannot achieve self-sustaining growth.
Severe Negative Profitability And Cash BurnDeeply negative gross profit and materially negative operating cash flow (-12.7m TTM) show the business is consuming cash faster than it generates revenue. Persistent cash burn constrains R&D, sales expansion, and requires external funding; this structural shortfall threatens runway absent rapid revenue improvement.
High Leverage Relative To EquityDebt of ~8.7m against ~1.9m equity (≈4.6x) leaves limited financial flexibility. High leverage increases refinancing and covenant risk, can force dilutive capital raises, and restricts the company’s ability to invest in commercialization or absorb setbacks over the medium term.
QLIFE FAQ
What was Qlife Holding AB’s price range in the past 12 months?
Qlife Holding AB lowest stock price was kr1.20 and its highest was kr5.70 in the past 12 months.
What is Qlife Holding AB’s market cap?
Qlife Holding AB’s market cap is kr57.75M.
When is Qlife Holding AB’s upcoming earnings report date?
Qlife Holding AB’s upcoming earnings report date is Aug 26, 2026 which is in 55 days.
How were Qlife Holding AB’s earnings last quarter?
Qlife Holding AB released its earnings results on May 13, 2026. The company reported -kr0.719 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.719.
Is Qlife Holding AB overvalued?
According to Wall Street analysts Qlife Holding AB’s price is currently Overvalued.
Does Qlife Holding AB pay dividends?
Qlife Holding AB does not currently pay dividends.
What is Qlife Holding AB’s EPS estimate?
Qlife Holding AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Qlife Holding AB have?
Qlife Holding AB has 28,874,178 shares outstanding.
What happened to Qlife Holding AB’s price movement after its last earnings report?
Qlife Holding AB reported an EPS of -kr0.719 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 8.817%.
Which hedge fund is a major shareholder of Qlife Holding AB?
Currently, no hedge funds are holding shares in SE:QLIFE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Qlife Holding AB
Operating as a medical technology firm, Qlife Holding AB (publ) specializes in the production and distribution of in-vitro diagnostic instruments and their associated chemical reagents. Their flagship offering is the Egoo.Health Platform, a comprehensive system comprising a measuring device, single-use test capsules, and integrated software. This innovative platform facilitates the detection of various biomarkers or viral agents, with each capsule tailored for a distinct diagnostic purpose. The range of supported biomarkers encompasses C-reactive protein for home-based monitoring, Phenylalanine (PHE) vital for managing Phenylketonuria (PKU) in patients, and a multiplex test designed to identify Sars-CoV-2 and Influenza, aiding in the detection of viral and bacterial infections. Established in 2019, Qlife's operations are headquartered in Helsingborg, Sweden.